Andrew Guggenhime Vaxcyte, Inc. (PCVX) insider trading activity

Andrew Guggenhime is PRESIDENT AND CFO of Vaxcyte, Inc.. Currently has a direct ownership of 124,309 shares of PCVX, which is worth approximately $5.3 Million. The most recent transaction as insider was on Sep 08, 2025, when has been sold 2,890 shares (Common Stock) at a price of $32.41 per share, resulting in proceeds of $93,664. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 124K

5.79% 3M change

37.54% 12M change

Total Value Held $5.3 Million

ANDREW GUGGENHIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 08 2025	SELL Payment of exercise price or tax liability	$93,664 $32.41 p/Share	2,890 Reduced 2.27%	124,309 Common Stock
Sep 02 2025	SELL Payment of exercise price or tax liability	$160,324 $31.56 p/Share	5,080 Reduced 3.84%	127,199 Common Stock
Apr 07 2025	BUY Exercise of conversion of derivative security	$99,982 $20.93 p/Share	4,777 Added 3.49%	131,950 Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$274,628 $72.1 p/Share	3,809 Reduced 2.91%	127,173 Common Stock
Feb 28 2025	SELL Payment of exercise price or tax liability	$92,735 $73.02 p/Share	1,270 Reduced 0.96%	130,982 Common Stock
Feb 27 2025	BUY Grant, award, or other acquisition	-	22,761 Added 14.68%	132,252 Common Stock
Feb 18 2025	SELL Open market or private sale	$672,880 $84.11 p/Share	8,000 Reduced 6.81%	109,491 Common Stock
Feb 18 2025	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 6.37%	117,491 Common Stock
Jan 21 2025	SELL Open market or private sale	$696,080 $87.01 p/Share	8,000 Reduced 6.81%	109,491 Common Stock
Jan 21 2025	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 6.37%	117,491 Common Stock
Dec 18 2024	SELL Open market or private sale	$711,040 $88.88 p/Share	8,000 Reduced 6.81%	109,491 Common Stock
Dec 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 6.37%	117,491 Common Stock
Nov 18 2024	SELL Open market or private sale	$691,040 $86.38 p/Share	8,000 Reduced 6.81%	109,491 Common Stock
Nov 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 6.37%	117,491 Common Stock
Oct 25 2024	BUY Exercise of conversion of derivative security	$399,930 $20.93 p/Share	19,108 Added 14.86%	109,491 Common Stock
Oct 18 2024	SELL Open market or private sale	$4,860,660 $115.73 p/Share	42,000 Reduced 31.73%	90,383 Common Stock
Oct 18 2024	BUY Exercise of conversion of derivative security	$224,699 $5.35 p/Share	42,000 Added 24.08%	132,383 Common Stock
Sep 18 2024	SELL Open market or private sale	$931,760 $116.47 p/Share	8,000 Reduced 8.13%	90,383 Common Stock
Sep 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.52%	98,383 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$698,020 $110.15 p/Share	6,337 Reduced 6.55%	90,383 Common Stock
Aug 19 2024	SELL Open market or private sale	$629,600 $78.7 p/Share	8,000 Reduced 7.64%	96,720 Common Stock
Aug 19 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.1%	104,720 Common Stock
Jul 18 2024	SELL Open market or private sale	$653,280 $81.66 p/Share	8,000 Reduced 7.64%	96,720 Common Stock
Jul 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.1%	104,720 Common Stock
Jun 18 2024	SELL Open market or private sale	$577,760 $72.22 p/Share	8,000 Reduced 7.64%	96,720 Common Stock

Also insider at

MTCR

Metacrine, Inc. Healthcare

Director

CRBU

Caribou Biosciences, Inc. Healthcare

Director